Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-04-02 Anti-androgens
| Cyproterone Acetate |
|
Formulary
|
Tablets 50mg For indications other than oncology |
 MHRA Drug Safety Update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma |
|
| Dutasteride Avodart® |
|
Formulary
|
Dutasteride is restricted for a high risk patient group, used in combination with tamsulosin in patients with moderate to severe symptoms (IPSS>12) with larger prostates (>30cc) and elevated PSA (>1.5ng/mL). |
|
LSCMMG: Dutasteride |
|
Links
LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Shared care Guideline - testosterone
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG: Dutasteride
- LSCMMG: Finasteride
- LSCMMG: SHARED CARE GUIDELINE: Testosterone (transdermal) As supplementation for postmenopausal women with low sexual desire if HRT alone is not effective
- LSCMMG: SHARED CARE GUIDELINE: Testosterone For hypogonadism due to testosterone deficiency in adult men
- LSCMMG: SHARED CARE GUIDELINE: Testosterone For hypogonadism due to testosterone deficiency in adult men
- LSCMMG: Testosterone (Testim® ) for female sexual dysfunction post oophorectomy or primary ovarian failure
- LSCMMG: Testosterone As supplementation for menopausal women with low sexual desire if HRT alone is not effective.
- LSCMMG: Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA Drug Safety update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA Drug Safety Update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA: Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)
- MHRA: Topical testosterone (Testogel): risk of harm to children following accidental exposure
- MHRA: Topical testosterone (Testogel): risk of harm to children following accidental exposure
- SHARED CARE GUIDELINE :As supplementation for postmenopausal women with low sexual desire if HRT alone is not effective